A delayed oligodendrocyte cell death after spinal cord injury (SCI) contributes to chronic demyelination of spared axons, leading to a permanent neurological deficit. Therefore, therapeutic approaches to prevent oligodendrocyte cell death after SCI should be considered. Estrogens are well known to have a broad neuroprotective effect, but the protective effect of estrogens on oligodendrocytes after injury is largely unknown. Here, we demonstrated that 17␤-estradiol attenuates apoptosis of oligodendrocytes by inhibiting RhoA and c-Jun-N-terminal kinase activation after SCI. Estrogen receptor (ER)-␣ and -␤ were expressed in oligodendrocytes of the spinal cord, and 17␤-estradiol treatment significantly inhibited oligodendrocyte cell death at 7 d after injury as compared with vehicle (cyclodextrin) control. 17␤-Estradiol also attenuated caspase-3 and -9 activation at 7 d and reduced the loss of axons from progressive degeneration. In addition, 17␤-estradiol inhibited RhoA and JNK3 activation, which were activated and peaked at 3 and/or 5 d after injury. Furthermore, administration of Rho inhibitor, PEP-1-C3 exoenzyme, inhibited RhoA and JNK3 activation, and decreased phosphorylated c-Jun level at 5 d after injury. Additionally, the attenuation of RhoA and JNK3 activation as well as oligodendrocyte cell death by 17␤-estradiol was reversed by ER antagonist, ICI182780. Our results thus indicate that 17␤-estradiol treatment improves functional recovery after SCI in part by reducing oligodendrocyte cell death via inhibition of RhoA and JNK3 activation, which were ER dependent. Furthermore, improvement of hindlimb motor function by posttreatment of 17␤-estradiol suggests its potential as a therapeutic agent for SCI patients. (Endocrinology 153: 3815-3827, 2012) 
O
ligodendrocytes undergo a delayed apoptosis in the white matter (WM) tract distant from the injury site for weeks after spinal cord injury (SCI) (1) (2) (3) . This secondary degenerative event in oligodendrocytes contributes to chronic demyelination of spared axons and exacerbates the extent of injury, leading to a permanent functional deficit after SCI (1, 4 -7) .
The mammalian Rho GTPase family consists of at least 14 different members: Rho (A, B, and C), Rac (1, 2, and 3), Cdc42, RhoD, RhoG, RhoH/TTF, TC10, and Rnd (1, 2, and 3) (8) . Rho GTPases act as intracellular molecular switches that transduce extracellular signals to the actin cytoskeleton. Rho GTPases are also involved in neuronal morphogenesis, axon growth and guidance, dendrite development, plasticity, and synapse formation (9) . In addition, Rho activation is known to block axon regeneration and participate in cell death after SCI (10) . Especially, RhoA activation after SCI is involved in oligodendrocyte apoptosis via p75 neurotrophin receptor activation (11, 12) . Therefore, RhoA appears to be a potential therapeutic target protein in view of promoting axonal repair after SCI.
The c-Jun N-terminal kinase (JNK) pathways typically are activated by proinflammatory as well as various stress signals in the nervous system (13) . JNK3, one isoform of three JNK (JNK1, -2, and -3), is selectively expressed in the nervous system (14) and is implicated in the apoptotic cell death under a wide range of pathological conditions, such as ischemia (15, 16) , axotomy (17, 18) , and seizure (19) and in animal models of neurodegenerative diseases (20, 21) . Recent evidence also shows that JNK3 activity is increased and sustained in a prolonged manner until several days after SCI, and apoptotic cell death of oligodendrocytes is reduced in JNK3 Ϫ/Ϫ , suggesting that the JNK3 pathway is involved in oligodendrocyte cell death after SCI (22) .
Estrogens can be a potential therapeutic agent for the treatment of many neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, stroke, and brain trauma because it has a broad neuroprotective effect against a variety of insults to the central nervous system (23) (24) (25) (26) . Our previous report also shows that 17␤-estradiol improves functional recovery by inhibiting apoptosis of neurons after SCI (27) , which is mediated through pERK-induced cAMP response element-binding protein-dependent bcl-2 induction (28) . However, the protective effect of estrogens on oligodendrocyte cell death after SCI is largely unknown. Because preservation of myelinated axons has a direct correlation with functional outcome after injury, here we examined whether 17␤-estradiol exerts its protective effect on oligodendrocyte cell death after SCI and whether RhoA and JNK3 pathways are implicated in its protective effect. Our data indicate that estrogen improved functional recovery after SCI by reducing apoptotic cell death of oligodendrocytes via inhibition RhoA-JNK3 activation, which is through the estrogen receptor (ER).
Materials and Methods

Spinal cord injury
Adult male Sprague Dawley [Sam:TacN (SD) BR; Samtako, Osan, Korea] rats were subjected to moderate 25 g-cm contusion injury as described previously (12) . Surgical interventions and postoperative animal care were performed in accordance with the Guidelines and Policies for Rodent Survival Surgery provided by the Animal Care Committee of the Kyung Hee University. For details on SCI, see Supplemental Methods (published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org).
Oligodendrocyte culture
Primary cultures of rat cortical oligodendrocytes were prepared as described previously (12) . For details on oligodendrocyte culture, see Supplemental Methods.
Drug administration
17␤-Estradiol (2-hydroxypropyl-␤-cyclodextrin-encapsulated; Sigma Aldrich, St. Louis, MO) was dissolved in sterile 0.1 M PBS (pH 7.4). For determination of optimal dose of 17␤-estradiol, rats receiving the 25 g-cm injury received iv injections of 17␤-estradiol at a dose of 100, 300, or 600 g/kg via tail vein within 5 min after SCI and then at 6 and 24 h with the same dose; the vehicle control group received injections of cyclodextrin in PBS with the same interval. As an optimal dosage, 300 g/kg 17␤-estradiol was selected and used throughout experiments (see Fig. 8A ). ER antagonist ICI182780 (Tocris Cookson, Inc., Ellisville, MO) was dissolved in 50% dimethylformamide in 0.9% saline and was given (3 mg/kg, ip) before each injection of 17␤-estradiol.
Tissue preparation
At specific time points after SCI, animals were anesthetized with chloral hydrate (500 mg/kg) and perfused via cardiac puncture initially with 0.1 M PBS and subsequently with 4% paraformaldehyde in 0.1 M PBS. A 20-mm section of the spinal cord, centered at the lesion site, was dissected out, postfixed by immersion in the same fixative overnight, and placed in 30% sucrose in 0.1 M PBS. The segment was embedded in OCT for frozen sections, and longitudinal or transverse sections were then cut at 10 or 20 m on a cryostat (CM1850; Leica, Wetzlar, Germany).
Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)
Seven days after injury, serial spinal cord sections (10 m thickness) were collected every 200 m and processed for TUNEL staining using an Apoptag in situ kit (Millipore, Billerica, MA). For details, see Supplemental Methods.
Immunostaining
Frozen sections were blocked with 5% normal serum and 0.1% Triton X-100 in PBS for 1 h at room temperature and then incubated with primary antibodies of phosphorylated c-Jun (pc-Jun) (1:100; Cell Signaling Technology, Danvers, MA), cleaved caspase-3 (1:100; Millipore), ER-␣ (1:100; Santa Cruz Biotechnology, Santa Cruz, CA), ER-␤ (1:100; Millipore), CC1 (1:100; Millipore), neuronal nuclei (NeuN), (1:200; Millipore), glial fibrillary acidic protein (GFAP) (1:5000; Millipore), OX-42 (1:100; Millipore), and myelin basic protein (MBP) (1:500; Millipore) overnight at 4 C. For double labeling, fluorescein isothiocyanate (FITC)-or Cy-3-conjugated secondary antibodies (Jackson Laboratories, Danvers, MA) were used. Also, nuclei were labeled with 4Ј,6-diamidino-2-phenylindole (DAPI) according to the protocol of the manufacturer (Invitrogen, Carlsbad, CA). In all immunohistochemistry controls, reaction to the substrate was absent if the primary antibody was omitted or if the primary antibody was replaced with a nonimmune, control antibody. Some serial sections were also stained with cresyl violet acetate for histological analysis. For quantification of p-c-Junpositive neurons or oligodendrocytes, serial transverse sections (10 m thickness) were collected every 100 m from 8 mm rostral to 8 mm caudal to the lesion epicenter (total 160 sections), and double-positive neurons (p-c-Jun ϩ NeuN) in the lower ventral horn of gray matter (GM) and oligodendrocytes (p-c-Jun ϩ CC1) in the lateral and ventral funiculus of WM were manually counted and averaged. The quantification of cleaved caspase-3-positive oligodendrocytes (cleaved caspase-3 ϩ CC1) was performed by same method for quantification of p-c-Jun-positive oligodendrocyte as described above.
Western blot
Segments of spinal cord (1 cm) were isolated containing the lesion site as the epicenter, and the tissue homogenates were prepared as previously described (12) . Tissue homogenate was centrifuged twice at 13,000 ϫ g for 10 min at 4 C, and the protein levels of the supernatant were determined using the bicinchoninic acid assay (Pierce, Rockford, IL). For analyses by Western blot, 50 g protein was separated by 12% SDS-PAGE and transferred to nitrocellulose membranes (Millipore) by electrophoresis. The membranes were blocked with 5% nonfat skim milk or BSA in Tris-buffered saline with 0.1% Tween 20 for 1 h at room temperature and then incubated with a primary antibodies against p-c-Jun (1:1000; Cell Signaling Technology), cJun, (1:500; Santa Cruz Biotechnology), cleaved caspase-3 (1: 1000; Cell Signaling Technology), caspase-9 (1:500; Santa Cruz Biotechnology), JNK1/2, (1:1000; Cell Signaling Technology), His-tag (1:1000; Santa Cruz Biotechnology), RhoA (1:1000; Santa Cruz Biotechnology), ER-␣ (1:100; Santa Cruz Biotechnology), and ER-␤ (1:100; Millipore) overnight at 4 C. The membranes were then processed with horseradish peroxidase-conjugated secondary antibody (Jackson Laboratories). Immunoreactive bands were visualized by chemiluminescence using Supersignal (Pierce). Experiments were repeated three times to ensure reproducibility.
RNA isolation and RT-PCR
Total RNA isolation using Trizol reagent (Invitrogen), cDNA synthesis, and RT-PCR were performed as previously described (29) . For details on RNA isolation and RT-PCR, see Supplemental Methods.
Pull-down assay for RhoA activity
Purification of glutathione S-transferase (GST)-Rho-binding protein domain (RBD) was performed as described previously (11) . For details on purification of GST-RBD, see Supplemental Methods. Frozen spinal cord tissue was homogenized in a modified radioimmunoprecipitation assay buffer containing 50 mM Tris (pH 7.2), 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 500 mM NaCl, 10 mM MgCl 2 , 10 g/ml aprotinin, 10 g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride. The homogenates were clarified by centrifugation twice for 10 min at 13,000 ϫ g at 4 C. The supernatant was incubated for 50 min at 4 C with GST-RBD-coupled beads (30 g/sample). The beads were washed four times with lysis buffer and eluted in sample buffer. GTP-bound RhoA and total RhoA present in tissue homogenates were detected by Western blot as described previously (12) .
Protein kinase assay
Frozen spinal cord tissue was homogenized in a Nonidet P-40 lysis buffer. The homogenates were clarified by centrifugation twice for 10 min at 13,000 ϫ g at 4 C. The supernatant were used for kinase assay. To assay for total JNK activity (JNK1-3), tissue extracts were incubated with recombinant GST-c-jun bound to glutathione-coupled Sepharose-beads, and [␥-32 P]ATP. The complex was washed extensively with lysis buffer.
Kinase activity in the complex was assayed by autoradiographic detection of labeled [␥-32 P]ATP. To assay for the JNK3-specific kinase activity, the cell lysates were first subjected to immunoprecipitation with the specific anti-JNK1 and -2 antibodies (Santa Cruz Biotechnology) to remove both JNK1 and JNK2 from the lysates. The remaining kinase activity (JNK3) in the supernatant was assayed by the capture JNK assay as described above. To ensure that JNK1 and -2 were completely removed from the supernatant, the supernatant was also examined by immunoblot analysis using the JNK1/2 antibody.
Axon staining and counting
At 38 d after injury, frozen sections were prepared as described above. Axons were stained using an antibody specific for 200-kDa neurofilament protein (NF200, 1:2000; Sigma). The quantitative analysis of axonal density is described in Supplemental Methods.
Retrograde tracing
Retrograde tracing using fluorogold (FG; Invitrogen) (30) was used to determine the extent to which spared descending axons reached the rostral lumbar enlargement. For details on retrograde tracing, see Supplemental Methods. The total number of FG-labeled neuronal cell bodies in selected supraspinal regions, the ventral medullary reticular formation (MdV), the lateral vestibular nucleus (LVe), the caudal pontine reticular formation (PnC), and the red nucleus (RN), was counted according to previously described methods (30) . Axons from these nuclei project to the thoracolumbar spinal cord and play important roles in hindlimb locomotor function (30, 31) .
Expression and administration of PEP-1-C3 protein
To introduce C3 exoenzyme (Clostridium botulinum) as a RhoA inhibitor into spinal cord, we fused PEP-1 sequence (KETWWETWWTEWSQPKKKRKV) to the N terminus of the C3 exoenzyme containing His-tag (32) (Supplemental Fig. 1A ). The expression and purification of both recombinant PEP-1-C3 and C3 fusion protein was performed as previously described (32) (Supplemental Fig. 1 , B and C). PEP-1-C3 (300 g/kg) protein was administrated by intrathecal infusion using Alzet osmotic minipump (Alzet 2001; Durect Corp., Cupertino, CA) according to manufacturer's instruction. Briefly, a mini-pump was filled with PEP-1-C3 and a catheter connected to the outlet of the mini-pump was inserted into the intrathecal space of the spinal cord at T9 through a small hole in the dura of T11-12. The tube was sutured to the spinous process just caudal to the laminectomy to anchor it in place. To examine delivery efficacy of PEP-1-C3 in vivo, the purified PEP-1-C3 was labeled with FITC (Pierce) according to the manufacturer's instructions and was injected intrathecally (300 g/kg) immediately after injury. Five days after injection, spinal cord tissues were prepared and sectioned and were processed for immunohistochemical staining using specific cell type markers. The fluorescence was photographed with an Olympus microscope with software accompanying the Cool SNAP camera (Roper Scientific, Ottobrunn, Germany).
Behavioral tests
Behavioral analyses were performed according to previously described methods (33) (34) (35) (36) . For details on behavioral tests, see Supplemental Methods.
Statistical analysis
Data except behavior tests are presented as the mean Ϯ SD values, and behavioral data are presented as the mean Ϯ SEM. Comparisons between vehicle and 17␤-estradiol-treated groups were made by unpaired Student's t test. Multiple comparisons between groups were performed by one-way ANOVA. Behavioral scores from Basso, Beattie, and Bresnahan analysis and inclined plane tests were analyzed by repeated-measures ANOVA (time vs. treatment). Tukey's multiple comparison was used as post hoc analysis. Statistical significance was accepted with P Ͻ 0.05. All statistical analyses were performed by using SPSS version 15.0 (SPSS Science, Chicago, IL).
Results
Oligodendrocytes express ER␣ and -␤
We first examined whether oligodendrocytes express ER-␣ and ER-␤. First, primary oligodendrocyte cultures were prepared as described in Materials and Methods. As shown in Fig. 1A , differentiated oligodendrocytes expressed both ER-␣ and ER-␤ mRNA. ER-␣-and ER-␤-positive cells were also colocalized with MBP, an oligo- dendrocyte cell-specific marker (Fig. 1B) . Next, to examine ER-␣ and ER-␤ expression in the spinal cord, total lysates were prepared from sham and injured spinal cord (at 5 d). Both ER-␣ and ER-␤ were expressed in the uninjured spinal cord (Fig. 1 , C and D), whereas the levels were not changed after SCI. When we performed Western blot for ER-␤, the antibody strongly recognized an approximately 53-kDa signal, although several signals were faintly detected. When the membrane was stripped and reprobed with ER-␤ antibody after preabsorption to its corresponding peptide, the expected ER-␤ band (53 kDa) was greatly diminished, whereas the intensity of other bands did not change, indicating that the 53-kDa signal was specific for ER-␤. To identify the cell types, we performed double immunostaining with antibodies against ER-␣ and ER-␤ and the cell-type-specific markers NeuN for neurons, CC1 for oligodendrocytes, GFAP for astrocytes, and OX-42 for microglia. As shown in Fig. 1 , E and F, double labeling showed that in the uninjured normal spinal cord, neurons in the GM and oligodendrocytes in the WM were positive for both ER-␣ and ER-␤.
17␤-Estradiol attenuates apoptosis of oligodendrocytes after SCI
It is well known that estrogens exhibits neuroprotective effects against a variety of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, stroke, and brain trauma (23) (24) (25) (26) . Our previous report also shows that 17␤-estradiol improves functional recovery after SCI by inhibiting apoptotic cell death of neurons via increasing cAMP response element-binding protein-dependent bcl-2 expression (27, 28) . However, the protective effect of estrogens on oligodendrocyte cell death after SCI has not been examined. Thus, we hypothesized that 17␤-estradiol would inhibit oligodendrocyte cell death after SCI. Rats received iv injections of 17␤-estradiol (300 g/kg), which is the most effective dose (see Fig. 8A ), 5 min and 6 and 24 h after injury with the same dose; the vehicle control group received injections of cyclodextrin in PBS with same interval. Seven days after injury, quantification of TUNEL-positive cells showed that 17␤-estradiol administration reduced apoptotic cell death in the WM compared with vehicle control (Fig. 2, A and B) (17␤-estradiol, 32 Ϯ 4.0 vs. vehicle, 49 Ϯ 3.5). By double staining, many of these TUNEL-positive cells were positive for an oligodendrocyte-specific marker, CC1 (Fig. 2C) . More TUNEL-positive cells were observed from rostral to caudal from the lesion epicenter (data not shown). No signal was observed in sham-operated animals ( Fig. 2A) . 
17␤-Estradiol inhibits caspase-3 and -9 activation after SCI
Because 17␤-estradiol inhibits apoptotic cell death of oligodendrocyte (see Fig. 2 , A-C), and several reports also show that caspase-3 and -9 are activated and involved in delayed oligodendrocyte apoptosis after SCI (37-39), we expected that 17␤-estradiol might inhibit caspase-3 and -9 activations after SCI. By Western blot, caspase-3 and -9 were activated at 5 and 7 d (Fig. 2D) as reported previously (38) , and 17␤-estradiol treatment significantly inhibited their activation when compared with vehicle control (Fig.  2, E and F (Fig. 2G) . Counting of double-positive cells (caspase-3/CC1) revealed that 17␤-estradiol significantly reduced the numbers of caspase-3/CC1-positive oligodendrocytes compared with vehicle control (Fig. 2H) 
17␤-Estradiol inhibits RhoA activation after SCI
Because RhoA activation is known to be involved in axonal degeneration (40) and in oligodendrocyte cell death after SCI (11, 12, 41) , we hypothesized that 17␤-estradiol would inhibit RhoA activation after SCI. RhoA activation by Rho pull-down assay was evaluated by probing tissue extracts with the RBD from the Rho-GTP-interacting protein rhotekin as described in Materials and Methods. The level of GTP-bound RhoA was increased and peaked at 5 d after SCI as reported (12) (see Fig. 4 , A and B). Expression levels of total RhoA, as detected by Western blots from tissue extracts used for isolation of GTP-RhoA, was not changed (Fig. 3A) . Furthermore, 17␤-estradiol significantly inhibited RhoA activation when compared with vehicle control at 5 d (Fig. 3 , C and D) (estradiol, 1.03 Ϯ 0.04 vs. vehicle, 0.43 Ϯ 0.07).
17␤-Estradiol inhibits JNK3 activation and c-Jun phosphorylation
JNK3 activation has been shown to be involved in oligodendrocyte apoptosis through c-Jun phosphorylation (42, 43) . Moreover, recent evidence shows that after SCI, JNK3 activation is implicated in predominantly oligodendrocyte apoptosis but not in neuronal cell death (22) . Thus, we postulated that after SCI, 17␤-estradiol would protect oligodendrocytes by inhibiting JNK3 activity. To assess JNK3-specific activity, JNK1 and -2 isoforms were immunodepleted with antibodies against JNK1 and -2. After depletion, there was very little or no JNK1 and -2 protein remaining as judged by Western blot with antibody against JNK1/2 (Fig. 3E) . Therefore, the residual JNK activity could represent JNK3 activation. The measured JNK3 activity was increased and peaked at 3-5 d after injury (Fig. 3, E and F) . Furthermore, 17␤-estradiol significantly reduced the JNK3 activation at 5 d when compared with vehicle control (Fig. 3, G and H) (estradiol, 0.41 Ϯ 0.07 vs. vehicle, 1.02 Ϯ 0.03). By contrast, JNK1/2 expression was not changed by 17␤-estradiol (Fig. 3G) .
The phosphorylation of c-Jun by JNK3 is also implicated in neuronal and oligodendroglial cell death in cerebral hypoxic-ischemic brain injury (44) and SCI (22) . As a downstream activator of JNK3, we anticipated that 17␤-estradiol would also reduce the level of p-c-Jun after SCI. There was little expression of p-c-Jun in sham-operated controls. However, injury to the spinal cord caused early increase of p-c-Jun level at 1 d (Fig. 4, A and B) as reported (45) . At delayed time points (at 5-7 d), the level of p-c-Jun was also increased (Fig. 4, A and B) . Furthermore, 17␤-estradiol significantly reduced the level of p-c-Jun compared with vehicle control (Fig. 4 , C and ) at 7 d (estradiol, 0.38 Ϯ 0.04 vs. vehicle, 1.03 Ϯ 0.06). These results were also confirmed with double immunohistochemical detection and counting the number of p-c-Jun-positive cells at 1 and 7 d. In contrast to sham controls, which showed no p-c-Jun-positive signal (Fig. 4E, Sham) , intense signals for p-c-Jun were detected in neurons and oligodendrocytes at 1 and 7 d (Fig. 4E) . When p-c-Jun-positive cells were counted and analyzed at 1 d, most p-c-Jun immunoreactivity was detected in neurons in the GM. However, the number of p-c-Jun-positive oligodendrocytes was increased 2.5-fold at 7 d when compared with that at 1 d, whereas the number of p-c-Jun-positive neurons was decreased (Fig. 4 , E and F). Next, to investigate whether c-Jun phosphorylation might be involved in apoptotic cell death of oligodendrocytes, TUNEL staining was performed with immunostaining with p-c-Jun antibody using spinal tissues from 7 d. As shown in Fig. 4G , many p-cJun-positive oligodendrocytes in the WM were positive for TUNEL, indicating that c-Jun phosphorylation is involved in the apoptotic cell death of oligodendrocytes at 7 d after SCI.
17␤-Estradiol prevents axonal loss after SCI
It is known that axonal loss via wallerian degeneration and axon dieback occurs after SCI (46, 47) . In addition, inactivation of Rho or its downstream target Rho-associated kinase (ROCK) is known to promote central nervous system axon regeneration of crushed optic nerves in adult rats (48) and stimulates axon regeneration after SCI, leading to recovery of hindlimb function (49) . Furthermore, our data showed that 17␤-estradiol inhibited RhoA activation after injury (see Fig. 3C ). Thus, we hypothesized that 17␤-estradiol would reduce axonal loss after SCI. When we counted the number of NF200-positive axons in the preselected areas of the WM after staining with NF200 using cross-sections from at 38 d after injury, we observed that axon loss occurred rostrally and caudally from the lesion epicenter (Fig. 5, A and B) . However, 17␤-estradiol treatment markedly reduced the extent of axon loss compared with vehicle control (Fig. 5, A and B) . Next, we performed retrograde tracing to assess the extent of spared or regenerated descending axons using a retrograde tracer, FG. Notably, the mean number of FG-labeled neurons in selected supraspinal nuclei in the brain was significantly higher in the 17␤-estradiol-treated group than in vehicle control (Fig. 5, C and D 
RhoA activation mediates JNK3 activation after SCI
Our data showed that both RhoA and JNK3 were activated at a delayed time after injury, and estrogen significantly attenuated RhoA and JNK3 activation, leading to inhibition of oligodendrocyte cell death. Next, to examine the role of RhoA activation in oligodendrocyte cell death and the relationship between RhoA and JNK3, we constructed the expression vector of PEP-1-exoenzyme C3 (PEP-1-C3) fusion protein to use as an inhibitor for RhoA (Supplemental Fig. 1, A and B) , which can be inactivated by ADP ribosylation via C3 transferase of C. botulinum (50) . PEP-1-C3 proteins were purified and further confirmed with matrix-assisted laser desorption/ionizationtime of flight mass spectrometry (data not shown) and Western blot with antibody against His-tag for protein identification (Supplemental Fig. 1C) . To investigate the ability of PEP-1-C3 protein to transduce into cells, matured oligodendrocyte cultures were incubated with PEP-1-C3 (10 and 50 g/ml) for indicated time periods. As shown in Supplemental Fig. 1, D and E, PEP-1-C3 effectively entered into oligodendrocytes, and the level peaked at 3 h after incubation. To examine the delivery efficacy of PEP-1-C3 in the spinal cord, PEP-1-C3 (300 g/kg) was labeled with FITC and intrathecally injected into the cord. Locally infused PEP-1-C3-FITC was also effectively transduced into neurons, oligodendrocytes, astrocytes, and microglia (Supplemental Fig. 1F) .
Next, we examined the effect of PEP-1-C3 on RhoA activation and oligodendrocyte cell death after SCI. As shown in Fig. 6 , A and B, transduced PEP-1-C3 significantly inhibited RhoA activation at 5 d after SCI compared with vehicle control (C3), which was not transduced into the spinal cord tissue as in our previous report (51) . In addition, the number of TUNEL-positive oligodendrocytes was significantly reduced in the PEP-1-C3-treated group compared with the vehicle group (C3, 53 Ϯ 5 vs. PEP-1-C3, 36 Ϯ 3) (Fig. 6C) . To investigate the relationship between RhoA and JNK3, we also assayed JNK3 activity and the level of p-c-Jun after PEP-1-C3 treatment. As shown in Fig. 6 , D and E, both JNK3 activity and the level of p-c-Jun at 5 d after injury were significantly decreased by PEP-1-C3 when compared with vehicle (C3) control.
17␤-Estradiol inhibits RhoA and JNK3 activation via ER
To examine whether the inhibition of SCI-induced RhoA and JNK3 activation and oligodendrocyte cell death by 17␤-estradiol might be mediated through ER, we employed ICI182780, an ER antagonist. It has been reported that ER-␣ has a 7-fold and ER-␤ has a 3-fold greater relative affinity to ICI182780 than to 17␤-estradiol (52) . After SCI, ICI182780 (3 mg/kg) was injected ip before 17␤-estradiol treatment, and GTP-bound RhoA level and JNK3 activity were measured. As shown in Fig.   FIG. 5 . 17␤-Estradiol reduces axon loss after SCI. After behavioral tests, spinal cords at 38 d after injury were processed and transverse cryosections were selected 3 mm rostrocaudal to the lesion site for neurofilament staining with NF200 antibody. A, Axon loss occurred after SCI compared with sham control. The number of NF-positive axons in the 17␤-estradioltreated group was higher than that in the vehicle (cyclodextrin)-treated group. Scale bar, 30 m. B, Quantitative analysis of neurofilament-stained axons within the vestibulospinal tract shows that the number of axons in the 17␤-estradiol-treated groups was significantly higher than in the vehicle groups. Data are mean Ϯ SD (n ϭ 5). *, P Ͻ 0.05 (ANOVA) vs. vehicletreated control. C, Axonal transport and/or axon sparing is increased by 17␤-estradiol after SCI. FG was applied to rats tested for behavior at the L1 site, and at 7 d after FG treatment, spinal and brain sections were prepared. Note that the number of FG-labeled neurons both in propiospinal (T6 and C7) and in four brainstem regions, MdV, LVe, PnC, and RN, was higher in 17␤-estradiol-treated groups than in vehicle-treated groups. Scale bar, 100 m. D, Quantification of FG-labeled neurons in spinal cord and brainstem. Data are mean Ϯ SD (n ϭ 5). *, P Ͻ 0.05 (Student's t test) vs. vehicle-treated control. ES, 17␤-Estradiol; Veh, vehicle.
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7, A and B, ICI182780 reversed the effects of 17␤-estradiol on RhoA and JNK3 activation after SCI. ICI182780 alone did not have an affect on RhoA and JNK3 activation (Fig.  7C ). In addition, the reduction in the number of TUNEL/ CC1-positive cells by 17␤-estradiol after SCI was also reversed by ICI182780 [estradiol ϩ dimethylsulfoxide (DMSO), 37 Ϯ 3.3 vs. estradiol ϩ ICI182780, 52 Ϯ 2] (Fig. 7D) .
Therapeutic dosage and time windows for 17␤-estradiol treatment after SCI
We previously showed that 17␤-estradiol treatment 1-2 h before and immediately after SCI improves functional recovery of hindlimb locomotion (27) . Therefore, it is indispensable to determine the dosage and time windows of 17␤-estradiol treatment for behavioral improvement in view of therapeutic approaches. After moderate (25 mm) SCI, 17␤-estradiol (100, 300, and 600 g/kg) was administered as described in Materials and Methods and examined the effect on functional recovery. As shown in Fig. 8A , BBB scores were significantly increased in 300-and 600-g/kg 17␤-estradiol-treated groups when compared with vehicle control, whereas 100-g/kg 17␤-estradiol-treated groups showed no significant effect. To determine the time windows of 17␤-estradiol, rats were divided into four groups (group 1, 2 h; group 2, 6 h; group 3, 12 h to first injection of 17␤-estradiol after injury; and vehicle-treated control group), and functional recovery was assessed by BBB test, inclined plane test, footprint analysis, and grid walk test. As shown in Fig. 8B, 17␤ estradiol treatment significantly increased BBB scores in either 2 or 6 h, whereas no significant effect was observed in the 12-h-after-injury group compared with vehicle control group. The angle capacity to sustain was also significantly higher in rats administered 17␤-estradiol 2 and 6 h after injury when compared with vehicle control (Fig. 8C) . After SCI, the degree of footfall frequency increased; for example, about 60% of footfall per total steps was observed in vehicle-treated rats. However, the grid error percentage in groups administered after a 2-and 6-h delay was significantly lower than that observed in vehicle control groups (Fig. 8D) . The representative footprint recordings also showed that rats treated with 17␤-estradiol endo.endojournals.orgwithin 2 and 6 h after injury had very little toe dragging and even fairly constant forelimb-hindlimb coordination (Fig. 8E) , whereas toe dragging and inconstant forelimbhindlimb coordination were observed in vehicle control and 17␤-estradiol-treated group at 12 h after injury. On the other hand, consistent forelimb-hindlimb coordination, no toe dragging, and no paw rotation were observed in sham control.
Discussion
Here we report that 17␤-estradiol protects oligodendrocytes from apoptotic cell death occurred after SCI by inhibiting RhoA and JNK3 activation, which are known to be involved in oligodendrocyte cell death after SCI (11, 22) . Furthermore, we first provide evidence that RhoA activation plays as an upstream activator for JNK3 phosphorylation after SCI. By inhibiting RhoA activation by 17␤-estradiol or PEP-1-C3 (RhoA inhibitor) after SCI, both JNK3 activation and the level of p-c-Jun were decreased. We also found that the inhibition of RhoA and JNK3 activation by 17␤-estradiol, thereby reducing oligodendrocyte cell death after SCI, was mediated through ER-␣ and/or -␤. Finally, we provide therapeutic dosage (300 g/kg) and time windows (2 and 6 h after injury) for 17␤-estradiol treatment after SCI in the rat. Our data showed that 17␤-estradiol significantly inhibited oligodendrocyte cell death and axon loss in the WM after SCI (see Figs. 2 and 6 ). Rho activation after SCI has been implicated in axonal degeneration (40) , and the inhibition of Rho or Rho kinase, an effecter of Rho, is known to promote axonal regeneration and functional recovery after SCI (49, 53) . RhoA activation is also involved in apoptotic cell death of neurons and oligodendrocytes after SCI (11) . Our study showed that RhoA was activated after SCI, and 17␤-estradiol significantly inhibited RhoA activation (see Fig. 3, A-D) . In addition, apoptotic cell death of oligodendrocytes after SCI was significantly inhibited by PEP-1-C3, a RhoA inhibitor (see Fig. 6 , D and E). Furthermore, our previous report also shows that minocycline inhibits oligodendrocyte cell death by alleviating RhoA activation after SCI (12) . Taken together, our results suggest that the inhibition of oligodendrocyte cell death and axon loss by 17␤-estradiol appears to be mediated by inhibition of RhoA activation after SCI.
Generally, estrogens are known to exert its effects via ER-dependent or -independent mechanisms (54 -57) . It is considered that physiological levels of 17␤-estradiol act through genomic mechanisms to protect neurons against ischemic insults (56, 58) , whereas the supraphysiological concentrations or pharmacological levels of estrogen act through nongenomic mechanisms such as by antioxidant activity (26, 59) . In this study, the pharmacological level of 17␤-estradiol was used. Thus, we suspect that the protective effect of 17␤-estradiol on oligodendrocyte cell death and functional improvement after SCI may be mediated through a nongenomic pathway. However, our data also showed that both ER-␣ and -␤ were expressed in both oligodendrocytes and neurons, and the attenuation FIG. 8. Therapeutic dosage and time windows for 17␤-estradiol treatment after SCI. To determinate the optimal dose, 17␤-estradiol (100, 300, and 600 g/kg) or vehicle (cyclodextrin) was administered immediately after injury and then again at 6 and 24 h. Functional recovery was assessed by BBB test. A, BBB score was significantly improved in 300-and 600-g/kg 17␤-estradiol-treated groups when compared with vehicle groups, whereas 100-g/kg 17␤-estradiol-treated groups showed no significant effect. To determine the therapeutic time windows, 17␤-estradiol (300 g/kg) was treated at 2, 6, or 12 h after injury and then further treated at 6 and 24 h. Functional improvement was assessed by BBB score (B), inclined plane test (C), grid walk test (D), and footprint analysis (E). Note that 17␤-estradiol treatment (after 2-or 6-h delay) significantly improved BBB score and reduced an error percentage in grid walk test when compared with vehicle control. However, 17␤-estradiol treatment after a 12-h delay showed no significant effect on recovery. Representative footprints showed that 17␤-estradiol treatment (after 2-or 6-h delay) improved foot coordination, whereas rats treated with vehicle and 17␤-estradiol at 12 h after injury showed inconsistent coordination and toe dragging. All data are mean Ϯ SEM (n ϭ 10). *, P Ͻ 0.05; **, P Ͻ 0.01 (ANOVA) vs. vehicle-treated control. ES, 17␤-Estradiol; Veh, vehicle. of RhoA and JNK3 activation by 17␤-estradiol was processed via ER-␣ and/or -␤-mediated signaling because ICI182780 reversed the inhibitory effect by 17␤-estradiol (see Fig. 7, A and B) . Furthermore, several ER-dependent mechanisms via modulation of the Bcl-2 family (56, 60), activation of phosphatidylinositol 3-kinase (57), MAPK (61) , and induction of heat-shock proteins have been reported (62) . Thus, we cannot rule out the possibility that ER-dependent mechanisms may also contribute to the inhibition of RhoA and JNK3 activation by 17␤-estradiol. Little is known regarding which mechanisms of RhoA activation underlying apoptotic cell death are involved. In this regard, only the facts that after serum deprivation, caspase-3 is required for Rho-mediated apoptosis (63, 64) and the activation of the JNK pathway can also occur in response to Rho activation (65) have been reported. Therefore, it is important to find the downstream signaling molecule affected by RhoA activation in apoptotic cell death of oligodendrocytes after SCI. JNK3 is known to play a preferential role in stress-induced neuronal apoptosis in brain (15, 19, 66) . Furthermore, a recent report shows that JNK3 participates in oligodendrocyte apoptosis after SCI (22) . Our data also show that JNK3 was activated and peaked at 3-5 d after SCI (see Fig. 3 , E and F), at the time in which oligodendrocyte cell death also peaked (see Fig. 2 ) (12) . In addition, 17␤-estradiol significantly inhibited JNK3 activity, which was dependent on ER-mediated signaling (see Fig. 7, A and B) . Furthermore, RhoA and JNK3 were activated at the same peak time (5 d) after SCI, and local infusion of PEP-1-C3, an inhibitor of RhoA, inhibited JNK3 activation. Thus, our results indicate that JNK3 is involved in oligodendrocyte cell death as a downstream molecule of RhoA activation, which is inhibited by 17␤-estradiol (Supplemental Fig. 2) .
It is well known that the phosphorylation of c-Jun occurs at an early time in degenerating and apoptotic neurons after ischemia, nerve fiber transection, UV irradiation (67), axotomy, other forms of neuronal and axonal injuries (68, 69) , and traumatic brain and spinal cord injuries (45, 70, 71) . According to previous reports showing that JNK1/2 activation occurs at an early time after SCI (22, 45) , the phosphorylation of c-Jun at 1 d after injury in the present study appears to be the result of early JNK1/2 activation. However, the level of p-c-Jun was increased at a delayed time (7 d) as well as at an early time (1 d) after injury (see Fig. 4A ). In addition, the number of p-c-Jun/ CC1-positve oligodendrocytes was increased at 7 d after injury, whereas the number of p-c-Jun/NeuN-positive neurons was decreased when compared with those at 1 d after injury (see Fig. 4 , E and F). These data suggest that the phosphorylation of c-Jun at a delayed time (7 d ) after injury appears to be regulated by JNK3 activation after SCI. In addition, p-c-Jun-positive oligodendrocytes were colocalized with TUNEL immunoreactivity at 7 d (see Fig.  4G ), implying that the phosphorylation of c-Jun at a delayed time is involved in apoptotic cell death of oligodendrocytes. Furthermore, this late c-Jun phosphorylation was inhibited by PEP-1-C3, an inhibitor of RhoA, and 17␤-estradiol (Figs. 4C and 8D) . Thus, our data suggest that the inhibition of oligodendrocyte cell death by 17␤-estradiol is likely mediated by inhibiting JNK3 activation followed c-Jun phosphorylation after SCI (Supplemental Fig. 2) .
In this study, 17␤-estradiol (100, 300, or 600 g/kg iv) was administered at 5 min and 6 and 24 h after injury to uncastrated male rats. When the physiological level (about 30 pg/ml in plasma of male rats) of 17␤-estradiol is considered (72), the dosage of 17␤-estradiol used in this study is the pharmacological level. However, any significant change in body weight and side effects was not observed among the experimental groups during the experiment (data not shown). Although it is also known that testosterone can be converted into estradiol by aromatase (73) , the possibility of the effect by aromatization of endogenous testosterone can be ruled out because the pharmacological level of 17␤-estradiol was used in this study. Thus, we believe that the neuroprotective effects of 17␤-estradiol were mainly exerted by exogenous 17␤-estradiol.
Finally, we determined therapeutic dosage and time windows for 17␤-estradiol treatment after SCI. Our previous report shows that in mild contusion injury (12.5 g-cm), 100 g/kg 17␤-estradiol significantly improved functional recovery (27) . However, after moderate (25 g-cm injury) injury, BBB scores were significantly increased by 300 and 600 g/kg 17␤-estradiol, whereas 100 g/kg 17␤-estradiol showed no significant effect (see Fig.  8A ). For time windows, functional recovery assessed by BBB score, incline test, grid walking, and footprint analysis was significantly improved in groups administered at 2 and 6 h after SCI (after treatment), whereas groups administered at 12 h after injury showed no beneficial effect (Fig. 8, B-E) . Thus, the determination of therapeutic windows provides the possibility that 17␤-estradiol can be used as a potential therapeutic agent for reducing oligodendrocyte cell death and axon loss, thereby improving functional recovery after SCI in humans.
